Who: Novartis/IFM Therapeutics
Novartis Goes All In On A Second Long-Term Bet With IFM
Pays $90m Up Front For IFM Due
Deal Snapshot: Novartis partnered with IFM Due in 2019 and has now exercised an option to buy the IFM Therapeutics subsidiary, continuing its ongoing relationship with the group.
More from Deals
• By
Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.